Abstracts tagged "Outcome measures"

Abstract Number: 0176 • ACR Convergence 2025
Development and Validation of an Accurate Patient Reported Outcome Measure-based Disease Activity Score to Enable Remote Monitoring in RA
Agnes Looijen¹, Paco Welsing², Sytske Anne Bergstra³, Annette van der Helm-van Mil³ and Pascal de Jong⁴, ¹Erasmus MC, Rotterdam, Netherlands, ²Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands, Utrecht, Netherlands, ³LUMC, Leiden, Netherlands, ⁴Erasmus University Medical Center, Rotterdam, the Netherlands, Rotterdam, Netherlands
Background/Purpose: For RA patients, regular monitoring of disease activity is essential, but in-person assessments may not always be feasible due to the increasing pressure on…
Abstract Number: 2496 • ACR Convergence 2025
Comparing Long-term Outcome Across Systemic Sclerosis Subgroups Using a Multi-Organ Disease Progression Score
Philip Yee¹, medha kanitkar², stefano rodolfi³, Voon H. Ong² and Christopher Denton⁴, ¹Division of Medicine, Centre for Rheumatology, University College London, London, England, United Kingdom, ²Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, ³University College London, London, United Kingdom, ⁴University College London, UK, London, United Kingdom
Background/Purpose: Evaluating disease modification in systemic sclerosis (SSc) is challenging and requires long term studies. This is especially relevant to limited cutaneous (lc)SSc where severe…
Abstract Number: 2308 • ACR Convergence 2025
Physical Function Mediates Most—but Not All—of the Effect of Disease Activity on Health-Related Quality of Life in Axial Spondyloarthritis: A 10-Year Longitudinal Analysis
AUGUSTA ORTOLAN¹, Désirée Van Der Heijde², Laure Gossec³ and Sofia Ramiro⁴, ¹Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France, ⁴Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Health-related quality of life (HRQoL) is an overarching outcome in axial spondyloarthritis (axSpA), and is considered influenced by disease activity and physical function. However,…
Abstract Number: 2055 • ACR Convergence 2025
Construct Validity of Total Improvement Score (TIS) as an Endpoint for Clinically Meaningful Improvement in Multiple Patient-Centered Outcome Measures in Dermatomyositis
Anjana Chandrasekhara Pillai¹, Shiri Keret², Siamak Moghadam-Kia³, Chester V. Oddis⁴ and Rohit Aggarwal⁵, ¹PPCP, Pittsburgh, PA, ²Bnai Zion Medical Center, Atlit, Israel, ³University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA
Background/Purpose: Total Improvement Score (TIS), as defined by the ACR/EULAR myositis response criteria, is increasingly employed as a primary endpoint in clinical trials for dermatomyositis…
Abstract Number: 1564 • ACR Convergence 2025
Validation of a Composite Endpoint for Systemic Sclerosis-Associated Interstitial Lung Disease
Elizabeth Volkmann¹, Holly Wilhalme², Samuel Good², Grace Kim², Jonathan Goldin², Michael Roth² and Donald Tashkin², ¹Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA, ²UCLA, Los Angeles
Background/Purpose: The forced vital capacity (FVC) is the most commonly used endpoint in registrational trials for systemic sclerosis-associated interstitial lung disease (SSc-ILD). However, the FVC…
Abstract Number: 1301 • ACR Convergence 2025
Prevalence, Clinical and Genetic Risk Factors, and Time to Cataract Development in Childhood-onset Systemic Lupus Erythematosus
Sirikarn Tangcheewinsirikul¹, Zhaoyu Ding², Nicholas Chan³, Daniela Dominguez³, Andrea Knight⁴, Deborah Levy¹, Lawrence Ng⁵, Earl Silverman¹, Ruud Verstegen¹ and Linda Hiraki¹, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²SickKids Research Institute, Toronto, ON, Canada, ³The Hospital for Sick Children, Toronto, Canada, ⁴Hospital for Sick Children, Toronto, ON, Canada, ⁵The Hospital for Sick Children, Toronto, Canada, Toronto, ON, Canada
Background/Purpose: Cataracts are a significant ocular complication in childhood-onset systemic lupus erythematosus (cSLE). This study aimed to assess the prevalence, time to cataract development, and…
Abstract Number: 1041 • ACR Convergence 2025
Associated Factors And Direct Cost Analysis Of Dose Reduction And Discontinuation Of Biological Therapies In Rheumatoid Arthritis And Spondyloarthritis: Findings From A Colombian Cohort Within The Framework Of An Integrated Management Model
Edwin Jauregui¹, Deisy Restrepo², Belcy Garzon², Alexis Atuesta², Nestor Correa², Jessica Barrera² and Andrea Rubio², ¹Riesgo de fractura S.A, Bogotá, Colombia, ²Riesgo de fractura S.A, Bogotá, Colombia
Background/Purpose: Dose reduction of biologic therapy (BT) in patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA) has been increasingly implemented in recent years, in accordance…
Abstract Number: 0785 • ACR Convergence 2025
It Takes a Community: Exploring the Importance of Community-Level Social Determinants of Health in Total Knee Arthroplasty Outcomes
Chloe Heiting¹, Yiyuan Wu², Susan Goodman³, Peter Sculco⁴, Fei Wang², Rich Caruana⁵, Peter Cram⁶, Said Ibrahim⁷ and Bella Mehta⁸, ¹Northwell Health, New Hyde Park, NY, ²Weill Cornell Medicine, New York, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁴Hospital for Special Surgery, New York, NY, ⁵Microsoft, Redmond, WA, ⁶University of Maryland School of Medicine, Baltimore, MD, ⁷Thomas Jefferson University, Philadelphia, PA, ⁸Hospital for Special Surgery, Weill Cornell Medicine, Jersey City, NJ
Background/Purpose: Despite changing trends and increased utilization of total knee arthroplasty (TKA) in the United States,1 there are still prominent racial and ethnic disparities in…
Abstract Number: 0398 • ACR Convergence 2025
Efficacy of Tumor Necrosis Factor Inhibitors in Children Diagnosed With Non-Systemic Juvenile Idiopathic Arthritis ≤ 2 Years Old Using The Childhood Arthritis and Rheumatology Research Alliance Registry
Christina Gulla¹, Tara Lozy² and Ginger Janow³, ¹Hackensack University Medical Center, Hackensack, NJ, ²Joseph M. Sanzari Children's Hospital, Center for Discovery and Innovation, Hackensack Meridian School of Medicine, Nutley, ³Joseph M. Sanzari Children's Hospital at Hackensack Meridian Health, Hackensack, NJ
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common pediatric rheumatic disease. Tumor necrosis factor inhibitors (TNFi) are key treatments in non-systemic JIA (sJIA), but…
Abstract Number: 0168 • ACR Convergence 2025
Risk of hospitalization in patients with rheumatoid arthritis-associated interstitial lung disease or bronchiectasis: A matched cohort study
QIANRU ZHANG¹, Ying Qi², Xiaosong Wang³, Gregory McDermott⁴, Sung Hae Chang⁵, Liya Sisay Getachew⁶, Mark Chaballa⁷, Vadim Khaychuk⁸, Misti Paudel⁹, Katherine Liao¹⁰ and Jeffrey Sparks⁶, ¹Brigham and Women’s Hospital/Beijing Tsinghua Changgung Hospital, Cambridge, MA, ²Brigham and Women’s Hospital, Boston, ³Brigham and Women's Hospital, Natick, MA, ⁴Brigham and Women's Hospital, Brookline, MA, ⁵Soonchunhyang University College of Medicine, Cheonan, MA, South Korea, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Bristol Myers Squibb, Princeton, NJ, ⁸Bristol Myers Squibb, Pennington, NJ, ⁹Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, ¹⁰Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Boston, MA, USA, Boston, MA
Background/Purpose: RA-associated lung disease (RA-LD), including RA-associated interstitial lung disease (RA-ILD) and RA-associated bronchiectasis (RA-BR), is a serious extra-articular manifestation of RA that significantly contributes…
Abstract Number: 2465 • ACR Convergence 2025
CD19/BCMA Dual-Targeting FasTCAR-T Cells GC012F (AZD0120) in patients with refractory Systemic Lupus Erythematosusm: an open-label, single-center Phase I study
chunmei Wu¹, Yakai Fu², Jia Liu³, Yan Ye⁴, Ran Wang⁵, Xintong Feng³, Lianjun Shen⁶, Peiying Li⁵, Shuang Ye⁵ and Qiong Fu⁷, ¹Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai, China (People's Republic), ²Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China (People's Republic), ³Astrazeneca, Shanghai, China (People's Republic), ⁴Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), ⁵Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai, Shanghai, China (People's Republic), ⁶Astrazeneca, Shanghai, Shanghai, China (People's Republic), ⁷Renji Hospital, Shanghai, Shanghai, China
Background/Purpose: GC012F (AZD0120) is a CD19/B cell maturation antigen (BCMA) dual-targeting chimeric antigen receptor T-cell (CAR-T) developed on the novel FasTCAR-T platform with next-day manufacturing,…
Abstract Number: 2307 • ACR Convergence 2025
Peripheral Manifestations In Axial And Peripheral Spondyloarthritis: A Systematic Literature Review On Their Assessment In Clinical Trials
AUGUSTA ORTOLAN¹, Casper Webers², Elena Nikiphorou³, Alexandre Sepriano⁴, Louise Falzon⁵, Clementina López Medina⁶, Dafne capelusnik⁷, Désirée Van Der Heijde⁸, Anna Molto⁹ and Sofia Ramiro¹⁰, ¹Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy, ²Maastricht University Medical Centre, Maastricht, Netherlands, ³King's College London, London, United Kingdom, ⁴Department of Rheumatology, Leiden University Medical Centre, Portela Loures, Portugal, ⁵Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield, United Kingdom, ⁶Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain, ⁷Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁹Assistance Publique Hôpitauxde Paris, Paris, France, ¹⁰Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Peripheral manifestations (peripheral arthritis, enthesitis, dactylitis) of axial spondyloarthritis (axSpA) and peripheral spondyloarthritis (pSpA) represent a significant burden for patients, but are understudied. Our…
Abstract Number: 2032 • ACR Convergence 2025
Validation of systemic Juvenile Arthritis Disease Activity Score 10 (sJADAS 10) in adult patients with Still’s Disease
Georgia-Savina Moysidou¹, Spyridon Katechis², Stéphane Mitrovic³ and Bruno Fautrel⁴, ¹Sorbonne université, Service de rhumatologie, groupe hospitalier Pitié-Salpêtrière, Assistance publique-Hôpitaux de Paris, Athens, Greece, ²National and Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ³Sorbonne université, Service de rhumatologie, groupe hospitalier Pitié-Salpêtrière, Assistance publique-Hôpitaux de Paris, Paris, France, ⁴Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS ¹¹³⁶-⁵, PARIS, France, Paris, France

Background/Purpose: Recent EULAR/PReS recommendations have acknowledged the lack of unique and consensual tool to quantify disease activity in Still’s disease (SD). The systemic Juvenile Arthritis…
Abstract Number: 1555 • ACR Convergence 2025
Prevalence of Organ Involvement and Baseline Predictors of Disease Progression in Patients with Limited Cutaneous Systemic Sclerosis: Insights from the CONQUER Database
Alain Lescoat¹, Virginia Steen², Monica Harding³, John VanBuren³, Brian Skaug⁴, Shervin Assassi⁵, Maureen Mayes⁶, Zsuzsanna McMahan⁷, Elana Bernstein⁸, Flavia Castelino⁹, Lorinda Chung¹⁰, Luke Evnin¹¹, Tracy Frech¹², Jessica Gordon¹³, Faye Hant¹⁴, Laura Hummers¹⁵, Kimberly Lakin¹³, Dorota Lebiedz-Odrobina³, Yiming Luo¹⁶, Ashima Makol¹⁷, Jerry Molitor¹⁸, Duncan Moore¹⁹, Carrie Richardson¹⁹, Nora Sandorfi²⁰, Ami Shah¹⁵, Ankoor Shah²¹, Elizabeth Volkmann²², Carleigh Zahn²³ and Dinesh Khanna²⁴, ¹CHU Rennes - University Rennes, Rennes, France, ²Georgetown University School of Medicine, Washington, DC, ³University of Utah, Salt Lake City, UT, ⁴UTHealth Houston Division of Rheumatology, Houston, TX, ⁵Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ⁶UT Health Houston Division of Rheumatology, Houston, TX, ⁷UT Health Houston, Houston, TX, ⁸Columbia University Irving Medical Center, New York, NY, ⁹Massachusetts General Hospital, Boston, MA, ¹⁰Stanford University, Stanford, CA, ¹¹Scleroderma Research Foundation, San Francisco, CA, ¹²Vanderbilt University Medical Center, Nashville, TN, ¹³Hospital for Special Surgery, New York, NY, ¹⁴Medical University of South Carolina, Charleston, SC, ¹⁵Johns Hopkins Rheumatology, Baltimore, MD, ¹⁶Columbia University Irving Medical Center, New York, ¹⁷Mayo Clinic, Rochester, MN, ¹⁸University of Minnesota, Minneapolis, MN, ¹⁹Northwestern University, Chicago, ²⁰University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, ²¹Duke University, Durham, NC, ²²Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA, ²³University of Michigan, Ann Arbor, ²⁴University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic sclerosis (SSc) is characterized by a wide range of clinical manifestations and available interventions still lack overall efficacy. Limited cutaneous SSc (lcSSc) and…
Abstract Number: 1300 • ACR Convergence 2025
International Assessment of cSLE Clinical Remission (cCR) Criteria in Childhood Lupus: Sensitivity Analyses from the UK JSLE Cohort and the CARRA Registry
Chandni Sarker¹, Jennifer Cooper², Emily Smitherman³, Flavia Alves¹, Alexandre Belot⁴, Michael Beresford⁵, Andreea Jorgensen¹, Eve Smith⁶, Laura Lewandowski⁷ and Rebecca Sadun⁸, ¹University of Liverpool, Liverpool, United Kingdom, ²University of Colorado/Children's Hospital Colorado, Aurora, CO, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Hospices Civils de Lyon, Collonges au mont d'or, France, ⁵Alder Hey Children's NHS Foundation Trust Hospital, Department of Women's & Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, United Kingdom, ⁶University of Glasgow, Glasgow, United Kingdom, ⁷NIAMS, NIH, Bethesda, MD, ⁸Duke University, Durham, NC
Background/Purpose: Consensus-derived treat-to-target (T2T) goals for childhood-onset SLE (cSLE), including clinical remission on low dose steroids (cCR), have been endorsed by the Paediatric Rheumatology European…

« Previous Page
1
…
5
6
7
8
9
…
59
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].